@basil15, you are correct. QBL work very closely with our Research partners in Israel. QBL may be a small cap company but we engage the highest level of security protocols to manage the flow of information.
It can be very easy to read/comment about what should be done for releasing scientific data and writing papers, but this is a highly specialized Cancer research laboratory, housed within a large world Research Institute, supported by the Israeli government, and one of the world's leading Cannabis Research centres who have some of the tightest security measures in the world. The Technion is not a Pharmaceutical company or private research lab. The security protocols are extreme, and the level of accountability of the highest order.
The Multiple Sclerosis announcement was also checked by the research team at 'The Technion' for suitability for publishing on a public platform to ensure the protection of the IP. It is in the best interests of the Technion and of QBL to ensure the protection of the IP, to preserve the value of this research for our shareholders for many years to come.
